Bristol-Myers Squibb has a well-defined strategy to transform itself into a BioPharma leader of the future. We are combining the passion and entrepreneurial spirit of a leading-edge biotech company with the experience and capabilities of a major pharmaceutical company.
One of the ways we are doing this is through our String of Pearls initiative.
String of Pearls is a strategic program of sequential transactions in which we secure a compound, a pipeline or an entire company. More important than what form a transaction takes is that it builds on our strategy and that it supports our company’s covenant to help patients prevail over serious disease. The opportunities we are looking for are highly targeted and are designed to either fill a particular need within a therapeutic area, to build upon an existing strength or to create a new area that we haven’t previously been in, but should be. As a result, not only are we interested in the potential medicines themselves, but also in the knowledge and science behind them.
Bristol-Myers Squibb has created a Strategic Transactions Group, a focused group that identifies and leads all the transactions of the company. The group integrates expertise and insights from across the organization and provides them directly to the company’s most senior decision-making body. It operates in a flexible manner to tailor and structure every transaction, and is charged with sourcing, evaluating and completing critical transactions as part of String of Pearls. This agile operating approach gives Bristol-Myers Squibb the ability to execute transactions swiftly and with the full commitment of the company.
The increasingly organic relationship between biotech and pharmaceutical companies provides an important ecology for innovation. Bristol-Myers Squibb understands the dynamics that are currently impacting smaller biotech companies. We firmly support targeted and appropriate relationships that both help biotech companies and the development of medicines that serve patients. We continue to look for partnerships with the best companies in the industry thereby supporting the industry as a whole.
At the end of the day, what we are trying to accomplish is to discover and develop important medicines.
We invite you to explore this site to get a deeper understanding of our unique approach to partnering and how we might be able to combine our strengths to bring new medicines to patients who need them.
March 17, 2009